LY-404187

LY-404187 is a potent and selective AMPAR potentiator. It has been shown to have potential use in the treatment of schizophrenia and related conditions, and has been investigated for its nootropic effects.

Pharmacology

LY-404187 is a potent and selective AMPA receptor potentiator, which means it enhances the activity of the AMPA receptor. The AMPA receptor is one of the three main types of ionotropic glutamate receptors, and it plays a key role in the fast synaptic transmission of excitatory signals in the brain.

LY-404187 has been shown to have potential use in the treatment of schizophrenia and related conditions. Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.

In addition to its potential use in the treatment of schizophrenia, LY-404187 has also been investigated for its nootropic effects. Nootropics, also known as "smart drugs", are substances that can improve cognitive function, particularly executive functions, memory, creativity, or motivation, in healthy individuals.

Clinical Trials

LY-404187 has undergone clinical trials to evaluate its safety and efficacy in the treatment of schizophrenia. The results of these trials have shown that LY-404187 is safe and well-tolerated, and it has demonstrated potential efficacy in improving the cognitive deficits associated with schizophrenia.

See Also

• AMPA receptor
• Schizophrenia
• Nootropics

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  LY-404187